DXCM DEXCOM INC.

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--

(NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.

The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast.

Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit .

Category: IR

EN
07/01/2025

Underlying

DXCMDEXCOM INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Revenue grew 8% year-over-year to $1.114 billion on a reported basis and 8% year-over-year on an organic1 basis. U.S. revenue grew 4% and international revenue grew 17% on a reported basis and 19% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $188.9 million or 17.0% of revenue, a decrease of 400 basis points compared to the fourth quarter of 2023. Non-...

February 13, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release ...

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 4...

January 30, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter a...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023. For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2...

January 13, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the sta...

January 7, 2025 1 EN
 PRESS RELEASE
Free
DXCM DEXCOM INC.

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. , the first over-the-counter glucose biosensor cleared2 by the FDA in the United States, is the first Dexcom product...

December 17, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch